Kyiv City Clinical Oncology Center

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

Richard S. Finn, John Crown, István Láng et al. · The Lancet Oncology · 2014 · 1.9K citations

Cyclin-dependent Kinase 4/6, Breast Oncology, Inhibitor Palbociclib +11

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer

Maha Hussain, Karim Fizazi, Fred Saad et al. · New England Journal of Medicine · 2018 · 1K citations · Full text

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

Philippe Moreau, Halyna Pylypenko, Sebastian Grosicki et al. · The Lancet Oncology · 2011 · 910 citations

Hematological Malignancy, Oncology, Relapsed Multiple Myeloma +7

Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double‐blind, placebo‐controlled trial

Sonia S. Hassan, Roberto Romero, D. Vidyadhari et al. · Ultrasound in Obstetrics and Gynecology · 2011 · 909 citations · Full text

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

Meletios Α. Dimopoulos, Philippe Moreau, Antonio Palumbo et al. · The Lancet Oncology · 2015 · 834 citations · Full text

Hematological Malignancy, Oncology, Dexamethasone Versus Bortezomib +8